102. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93–05 protocol. Int J Radiat Oncol Biol Phys. 2004;60(3):853–860. 103. Shrieve DC, Alexander E 3rd, Wen PY, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treat- ment of recurrent glioblastoma multiforme. Neurosurgery. 1995;36(2):275–282; discussion 282–274. 104. Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87–01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002;51(2):343–355; discussion 355–347. 105. Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1998;41(5):1005–1011. 106. Gabayan AJ, Green SB, Sanan A, et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-insti- tutional analysis. Neurosurgery. 2006;58(4):701–709; discussion 701–709. 107. Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine- 131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000;18(22):3862–3872. Malignant gliomas 108. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20(5):1389–1397. 109. ReardonDA,AkabaniG,ColemanRE,et al.Salvageradioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006;24(1):115–122. 110. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46(1–3):149–168. 111. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldﬁeld EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91(6):2076–2080. 112. Prados M, Kunwar S, Lang FF, et al. Final results of phase I/II studies of IL 13-PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant glioma. Proceedings of the American Society of Clinical Oncology Meeting. Orlando, USA. 2005. Abstract 1506. 113. Kunwar S, Westphal M, Medhorn M, et al. Results from PRECISE: a randomized phase 3 study in patients with ﬁrst recurrent glioblas- toma multiformed (GBM) comparing cintredekin besudotox (CB) administered via convection-enhanced delivery (CED) with Gliadel wafers (GW). Neuro Oncol. 2007;9(4):467–602 Abstract MA-61. Biologics:Targets & Therapy 2009:3 25